Skip to main content

Drug Interactions between K-Phos Original and Recede

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

benzphetamine potassium acid phosphate

Applies to: Recede (benzphetamine) and K-Phos Original (potassium acid phosphate)

MONITOR: Urinary acidifying agents such as ammonium chloride, sodium acid phosphate, and methenamine salts may lower the blood levels and efficacy of amphetamines. Acidifying the urine has been reported to increase the concentration of the ionized species of the amphetamine molecule, thereby inhibiting renal tubular absorption and increasing its urinary excretion. In one study, approximately 55% of an amphetamine dose was excreted unchanged when the urine was acidic, versus less than 3% when the urine was alkaline. Amphetamine half-life has also been reported to shorten by one-half or more when urine is acidic rather than alkaline. Acidification of the urine has been employed successfully in the treatment of amphetamine overdose.

MANAGEMENT: Patients receiving an amphetamine in combination with urinary acidifying agents should be monitored for potentially diminished pharmacologic response to the amphetamine.

References

  1. Anggard E, Jonsson LE, Hogmark AL, Gunne LM (1973) "Amphetamine metabolism in amphetamine psychosis." Clin Pharmacol Ther, 14, p. 870-80
  2. Davis JM, Kopin IJ, Lemberger L, Axelrod J (1971) "Effects of urinary pH on amphetamine metabolism." Ann N Y Acad Sci, 179, p. 493-501
  3. Beckett AH, Salmon JA, Mitchard M (1969) "The relation between blood levels and urinary excretion of amphetamine under controlled acidic and under fluctuating urinary pH values using [C]amphetamine." J Pharm Pharmacol, 21, p. 251-8
  4. Wilkinson GR, Beckett AH (1968) "Absorption, metabolism and excretion of the ephedrines in man. I. The influence of urinary pH and urine volume output." J Pharmacol Exp Ther, 162, p. 139-47
  5. Beckett AH, Rowland M (1965) "Urinary excretion kinetics of amphetamine in man." J Pharm Pharmacol, 17, p. 628-39
  6. Beckett AH, Rowland M, Turner P (1965) "Influence of urinary pH on excretion of amphetamine." Lancet, 1, p. 303
  7. Beckett AH, Rowland M (1965) "Urinary excretion kinetics of methylamphetamine in man." J Pharm Pharmacol, 17, s109-14
  8. Gary NE, Saidi P (1978) "Methamphetamine intoxication. A speedy new treatment." Am J Med, 64, p. 537-40
  9. (2001) "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham
View all 9 references

Switch to consumer interaction data

Drug and food interactions

Moderate

benzphetamine food

Applies to: Recede (benzphetamine)

GENERALLY AVOID: Alcohol may potentiate the central nervous system and cardiovascular effects of centrally-acting appetite suppressants. In one study, concurrent administration of methamphetamine (30 mg intravenously) and ethanol (1 gm/kg orally over 30 minutes) increased heart rate by 24 beats/minute compared to methamphetamine alone. This increases cardiac work and myocardial oxygen consumption, which may lead to more adverse cardiovascular effects than either agent alone. Subjective effects of ethanol were diminished in the eight study subjects, but those of methamphetamine were not affected. The pharmacokinetics of methamphetamine were also unaffected except for a decrease in the apparent volume of distribution at steady state.

MANAGEMENT: Concomitant use of centrally-acting appetite suppressants and alcohol should be avoided if possible, especially in patients with a history of cardiovascular disease. Patients should be counselled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References

  1. Mendelson J, Jones RT, Upton R, Jacob P 3rd (1995) "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther, 57, p. 559-68
  2. (2001) "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn
  3. (2012) "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer